NCT07166315

Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor

Clinical Characteristics, Treatment Patterns and Outcomes in Patients With axSpA and PsA Following Initiation of Bimekizumab, Risankizumab, Guselkumab, Upadacitinib or a TNF Inhibitor

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 700 (estimated)
• Sponsor: Adelphi Real World · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.

Detailed description

Patient experience surveys will be administered prospectively throughout the study period, whereas the review of patients' medical records will be conducted retrospectively towards the end of the study period.

Conditions

• Axial Spondylarthritis (axSpA)
• Psoriatic Arthritis (PsA)

Interventions

Type	Name	Description
OTHER	observational study	This is an observational study based on existing treatments prescribed prior to inclusion. No interventions are given as part of this research.

Timeline

• Start date: 2025-07-07
• Primary completion: 2027-03-01
• Completion: 2027-03-01
• First posted: 2025-09-10
• Last updated: 2025-09-10

Locations

1 site across 1 country: United Kingdom